In a randomized , open-label , 4-way crossover study , subjects received a randomized sequence of SC ondansetron 4 mg + rHuPH20 , or ondansetron monotherapy IM ( 4 mg ) , IV ( 4 mg ) , or PO ( 8 mg ) , over 4 daily visits .